Neuroleptic malignant syndrome (NMS)
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
Medication-Induced MovementG21.0
Loading…
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
Criteria met for major or mild NCD (substantial or modest cognitive decline in ≥1 domain)
Restriction of energy intake → significantly low body weight for age, sex, developmental trajectory, and physical health
Fine tremor occurring during attempts to maintain a posture that has developed in association with use of a medication
Depressed mood most of the day, more days than not, for ≥2 years (≥1 yr children/adolescents)
≥5 symptoms in final week before menses, improve within days of onset, become minimal/absent post-menses
Marked fear/anxiety about a specific object or situation
Intoxication: recent stimulant use; Withdrawal: cessation/reduction after prolonged heavy use
Involuntary athetoid or choreiform movements (lasting ≥4 weeks) of the tongue, jaw, trunk, or extremities that developed in association with use of a neuroleptic medication